Published in Medical Letter on the CDC and FDA, June 5th, 2005
According to a study from the United States, "The population pharmacokinetics of efalizumab was characterized in patients with moderate to severe plaque psoriasis. The study included 1,088 subjects who received 1 or 2 mg/kg/wk subcutaneous efalizumab for 12 weeks from a phase 1 (64 subjects) and 3 phase III studies with day 42 and/or day 84 trough levels (1024 patients). Due to the limitation of the data, a one-compartment model...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA